Intrinsic factor X-activating complex (iTenase)

The intrinsic factor X-activating complex, commonly referred to as the intrinsic tenase complex, is a critical multi-component enzyme assembly in the blood coagulation cascade. It consists of the serine protease activated Factor IX (FIXa), its essential cofactor activated Factor VIII (FVIIIa), calcium ions, and a procoagulant phospholipid surface, typically provided by activated platelets [StatPearls, "Physiology, Coagulation Cascade"]. The primary biological role of this complex is the efficient conversion of zymogen Factor X to its active form, Factor Xa, which is a rate-limiting step in the propagation phase of clot formation [PubMed, PMID: 11566327]. Deficiencies in the components of this complex lead to severe bleeding disorders, specifically Hemophilia A (FVIII deficiency) and Hemophilia B (FIX deficiency) [NIH, "Hemophilia"]. Modern therapeutic strategies target this complex either by replacing missing factors or by using bispecific antibodies like emicizumab, which mimics the scaffolding function of FVIIIa to bridge FIXa and FX, thereby restoring hemostasis in patients with inhibitors [NEJM, PMID: 28854339]. Because of its central role in thrombin generation, the complex is also a potential target for anticoagulant therapies aimed at preventing thrombosis with a lower risk of bleeding compared to traditional anticoagulants [Journal of Thrombosis and Haemostasis, PMID: 30160857].

Other names

Intrinsic tenase complexFIXa-FVIIIa complexFactor IXa-Factor VIIIa complexTenase complex

Replacement of coagulation factors to restore complex activity; Bispecific antibody bridging of Factor IXa and Factor X to mimic Factor VIIIa cofactor function [NEJM, PMID: 28854339; StatPearls, "Physiology, Coagulation Cascade"].